Tixel Treatment for Dry Eye Symptoms
NCT05299619 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2022-03-29
Summary
Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. Meibomian Gland Dysfunction (MGD) refers to the condition where the glands are not secreting enough oil or when the oil they secrete is of poor quality.
Tixel is a fractional skin rejuvenation system, which relies on direct thermal energy delivery, free of any radiation type such as laser, RF, etc. The energy is transferred via a continuously sterile, thermal titanium element (the "Tip"), located on the applicator (the "Handpiece"). In this study, the principal investigator will undertake standard treatment of periorbital wrinkles with Tixel and observe the effect on dry eye disease symptoms and signs.
Conditions
- Peri-orbital Wrinkles
- Dry Eye
Interventions
- DEVICE
-
Tixel
a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
Sponsors & Collaborators
-
Dr Ludger Hanneken
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-28
- Primary Completion
- 2022-02-22
- Completion
- 2022-03-28
Countries
- Andorra
Study Locations
More Related Trials
-
Evaluating Impact of Systane iLux on Dryness Symptoms and Wearing Time in Contact Lens Users
NCT05306561 ·Status: RECRUITING ·Phase: NA
-
Study of the TearCare System in Dry Eye Disease
NCT03588624 ·Status: COMPLETED ·Phase: NA
-
Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction
NCT04889950 ·Status: COMPLETED ·Phase: NA
-
Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome
NCT03162094 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Diamond Bur Microblepharoexfoliation, Intense Pulse Light and Meibomian Gland Expression for Evaporative Dry Eye
NCT05857579 ·Status: COMPLETED ·Phase: NA
-
Effect of Topical Antioxidants in Dry Eye Disease and Diabetic Retinopathy
NCT05429229 ·Status: UNKNOWN ·Phase: PHASE2
-
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes
NCT06898853 ·Status: RECRUITING ·Phase: NA
-
LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
NCT02365519 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
NCT03396913 ·Status: COMPLETED ·Phase: NA
-
Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction
NCT02958514 ·Status: COMPLETED ·Phase: NA
-
Mechanisms of Light-based Therapies for Dry Eye Disease
NCT06004895 ·Status: COMPLETED ·Phase: NA
-
Intense Pulsed Light in Meibomian Gland Dysfunction
NCT05089591 ·Status: UNKNOWN ·Phase: NA
-
Eyelid Androgen Treatment in Dry Eye
NCT06154200 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
NCT02621593 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease
NCT05865379 ·Status: RECRUITING ·Phase: NA
-
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
NCT05618730 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.
NCT06780306 ·Status: COMPLETED ·Phase: PHASE2
-
Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
NCT03658811 ·Status: COMPLETED ·Phase: NA
-
Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate
NCT01692652 ·Status: COMPLETED ·Phase: NA
-
Effect of Debridement-scaling on the Relief of Dry Eye Signs and Symptoms in Sjogren's Syndrome
NCT02203188 ·Status: COMPLETED ·Phase: NA
-
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
NCT02965846 ·Status: TERMINATED ·Phase: PHASE3
-
Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome
NCT02585648 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device
NCT03788486 ·Status: WITHDRAWN ·Phase: NA
-
Efficacy of 0.28% Sodium Hyaluronate Eye Drops in Patient with Moderate to Severe Dry Eye
NCT06860659 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction
NCT05159284 ·Status: RECRUITING ·Phase: PHASE4